Nano-X Imaging Ltd. Stock Price, News & Analysis

Nanox (Nasdaq: NNOX) will launch and demonstrate the FDA 510(k)-cleared Nanox.ARC X multi-source digital tomosynthesis system at RSNA 2025 (Nov 30–Dec 4, 2025) in Chicago. The Nanox.ARC X received FDA clearance in April 2025 for musculoskeletal, pulmonary, intra-abdominal and paranasal indications and is described as lower cost and lower radiation than CT. Live demos run every 30 minutes at Booth #3914. The company will also present clinical data, unveil a pulmonary nodule AI under development, and introduce two new AI tools for aortic valve calcification and body composition measurement.

Nanox (Nasdaq: NNOX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Thursday, November 20, 2025 before market open. Management will host a conference call and live webcast on the same day at 8:30 a.m. ET to review results and provide a business update. Registration and the live webcast will be available via the company website in the Investor Relations Events and Presentations section.

NANO-X IMAGING (Nasdaq: NNOX) on November 6, 2025 announced a distribution agreement with Czech imaging distributor EXRAY to introduce the Nanox.ARC multi-source digital tomosynthesis system across the Czech Republic.

EXRAY, founded in 2013, has installations in >50% of the country’s ~200 healthcare facilities and will lead market introduction, sales and service. The Nanox.ARC holds a CE Mark clearance for commercialization across the European Union.

Nanox (NASDAQ:NNOX) has announced a strategic collaboration with Monarch Medical Management and Billing LLC to deploy advanced medical imaging solutions across multiple healthcare segments. The partnership will establish a comprehensive imaging network initially spanning over a dozen proof-of-concept sites, with plans for nationwide expansion.

The collaboration will integrate Nanox's technology, including the Nanox.ARC 3D digital tomosynthesis system, AI-powered software for CT scan analysis, and teleradiology services across workers' compensation facilities, nursing homes, and outpatient clinics. This initiative aims to improve access to advanced imaging services and accelerate diagnosis and treatment decisions.

Nanox (NASDAQ: NNOX), a medical imaging technology company, reported its Q2 2025 financial results with revenue of $3.0 million, up from $2.7 million in Q2 2024. The company posted a net loss of $14.7 million, compared to $13.6 million in the prior year period.

Key developments include growing the Nanox.ARC system sales pipeline, plans to submit the TAP2D software module to FDA for 510(k) clearance, and a new partnership with Fabrinet for manufacturing support. The company expanded its presence in the U.S. and EU markets, with new customers including major imaging center chains and progress in Romania.

Nanox maintains its target of deploying over 100 units worldwide by end of 2025. As of June 30, 2025, the company held $62.6 million in cash and equivalents, down from $83.5 million at the end of 2024.

Nanox (NASDAQ:NNOX), a medical imaging technology company, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, before market open.

The company will host a conference call at 8:30 a.m. ET featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel, who will review the results and provide a business update. Investors can access the presentation through a live webcast available on the company's Investor Relations website.

Nanox (NASDAQ:NNOX) has announced a strategic clinical and educational collaboration with Keiser University to deploy its advanced Nanox.ARC 3D digital tomosynthesis imaging system at the university's Sarasota Campus. The system will be used for training healthcare professionals and will be incorporated into Keiser's Radiologic Technology graduate program.

The Nanox.ARC features a proprietary digital X-ray source and cold cathode technology, providing enhanced 3D imaging capabilities. Clinical studies have demonstrated the system's improved sensitivity and specificity compared to traditional X-ray, while achieving reduced radiation exposure and shorter radiologist reading times compared to CT scans.

The collaboration with Keiser University, which has awarded approximately 100,000 degrees and operates 19 Florida campuses, aims to educate prospective users about the Nanox.ARC's clinical value and increase the usage of various clinical protocols for patient benefit.

Nanox Imaging (NASDAQ: NNOX) announced that its Chief Financial Officer, Ran Daniel, will be presenting at the upcoming Investor Summit Virtual event scheduled for June 10, 2025. The virtual presentation represents an opportunity for the medical imaging technology company to communicate with investors and share company updates.

Nanox (NNOX) has received EU MDR CE mark certification for HealthOST, an AI-powered software for spine assessment that analyzes routine CT scans to detect vertebral height loss and bone mineral density. The software, which already has FDA 510(k) clearance from April 2022, helps identify musculoskeletal diseases like osteoporosis before fractures occur. HealthOST integrates with existing PACS systems and requires no additional imaging or radiation. The technology proved effective in the ADOPT study across four UK NHS trusts, identifying over 3,450 new patients with vertebral compression fractures from 37,220 CT scans - up to six times more than the national average. This advancement is particularly significant for Europe, where over 25.5 million women have osteoporosis, and annual fracture-related costs exceed €56 billion, with cases expected to increase 25% by 2034.